Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.
Flow Space on MSN9h
The Latest Science About GLP-1 Drugs & Weight Loss
Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?
The Next Web19h
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
High-cost weight loss drugs are sending employers to nutrition counseling in a boost for startups
Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...